Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review May 8, 2024May 8, 2024
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder August 31, 2023August 31, 2023
Alterity Therapeutics to Participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum March 15, 2022August 16, 2022